Answers are grounded in this paper and cite their sources.
Findings reveal that longer duration of response on first-line treatment improves overall survival in lung cancer, suggesting a need for better initial therapies.
Our findings demonstrate that patients with rwDOR ≥6 months on 1L combination IO and platinum chemotherapy exhibit longer rwOS on subsequent treatments. This emphasizes the need for 1L treatments that extend DOR and delay the onset of acquired resistance, which remains an unmet need for approximately 60% of patients who do not achieve a sustained response in clinical practice.
No takes yet. Share an insight, caveat, or question.
Malhotra et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: